Health economics studies in dermatology;Gesundheitsökonomische studien in der dermatologie

Hautarzt

Volumn 57, Issue 4, 2006, Pages 297-302

  Rogalski, C ^a,b   Simon, J ^a   Paasch, U ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b Klinik fur Dermatologie Venerologie und Allergologie   (Germany)

Author keywords

Cost benefit analysis; Cost effectiveness analysis; Cost minimization analysis; Cost utility analysis; Health economics

Indexed keywords

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DERMATOLOGY; EVALUATION; HEALTH CARE ACCESS; HEALTH ECONOMICS; MEDICAL SERVICE; PUBLIC HEALTH INSURANCE; PUBLICATION; RESOURCE ALLOCATION; REVIEW;

CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; COST CONTROL; COST-BENEFIT ANALYSIS; DERMATOLOGIC AGENTS; GERMANY; HEALTH CARE COSTS; HUMANS; NATIONAL HEALTH PROGRAMS; RESOURCE ALLOCATION; SKIN DISEASES;

EID: 33645452096     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-005-0982-x     Document Type: Review

References (20)

1. Augustin M (2002) Erfassung von Lebensqualität in der Dermatologie. http://www.awmf.de. 28-12-2004
2. Drummond MF, O'Brien B, Stoddart GL, Torrance GW (1997) Basic types of economic evaluation. In: Drummond MF (ed) Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford, pp 6-26
3. Drummond MF, O'Brien B, Stoddart GL, Torrance GW (1997) Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford
4. Ellis CN, Reiter KL, Wheeler JRC, Fendrick AM (2002) Economic analysis in dermatology. J Am Acad Dermatol 46: 271-283
5. Fleurence R (2003) An introduction to health economics. http://www.npc.co.uk. 28-12-2004
6. Freund DA, Dittus RS (1992) Principles in pharmacoeconomic analysis of drug therapy. Pharmaco Economics 1(1): 20-32
7. Hakkaart-van Roijen L, Verboom P, Redekop WK et al. (2001) The cost effectiveness of tapered versus abrupt discontinuation of oral cyclosporin microemulsion for the treatment of psoriasis. Pharmaco Economics 19(5 Pt 2): 599-608
8. Hannoveraner Konsensusgruppe (1999) Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation - Revidierte Fassung des Hannoveraner Konsens. Gesundheitsökonomie Qualitätsmanagement 4: A62-A65
9. Kurscheid T, Schrappe M, Lauterbach KW (2001) Kritische Bewertung gesundheitsökonomischer Studien. In: Lauterbach KW, Schrappe M (Hrsg) Gesundheitsökonomie, Qualitätsmanagement und Evidence-based Medicine. Schattauer, Stuttgart, S 107-118
10. Larko O, Swanbeck G (1982) Psoriasis treatment and a day-care centre: clinical aspects and an attempt at a cost-benefit analysis. Acta Derm Venereol 62(5): 413-418
11. Messori A, Becagli P, Trippoli S, Tendi E (1997) A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Eur J Cancer 33(9): 1373-1379
12. Morrell CJ, Walters SJ, Dixon S et al. (1998) Cost effectiveness of community leg ulcer clinics: randomised controlled trial. BMJ 316(7143): 1487-1491
13. Robinson R (1993) Economic evaluation in health care-what does it mean? BMJ 307:670-673
14. Schöffski O (2002) Grundformen gesundheitsökonomischer Evaluationen. In: Schöffski O, Schulenburg JM Graf v. d. (eds) Gesundheits-ökonomische Evaluationen. Springer, Berlin Heidelberg New York Tokyo, S 175-203
15. Schöffski OGW (2002) Das QALY Konzept zur Verknüpfung von Lebensqualitätseffekten mit ökonomischen Daten. In: Schöffski O, Schulenburg JM Graf v. d. (Hrsg) Gesundheits-ökonomische Evaluationen. Springer, Berlin Heidelberg New York Tokyo, S 367-399
16. Wasem JHF (2000) Gesundheitsbezogene Lebensqualität und Gesundheitsökonomie. http://www. uni-essen.de
17. Weiss SC, Kimball AB, Liewehr DJ et al. (2002) Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 47(4): 512-518
18. Wessels F, Anderson AN, Kropman K (1999) The cost-effectiveness of isotretinoin in the treatment of acne. Part 3. A cost-minimisation pharmacoeconomic model. S Afr Med J 89(7 Pt 2): 791-794
19. Williams H, Adetugbo K, Po A et al (1998) The Cochrane Skin Group. Arch Dermatol 134:1620-1626
20. Wootton R, Bloomer SE, Corbett R et al. (2000) Multicentre randomised control trial comparing real time teledermatology with conventional outpatient dermatological care: societal cost-benefit analysis. BMJ 320(7244): 1252-1256